MAP2K2

Across TCGA pan-cancer cohorts, MAP2K2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MAP2K2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MAP2K2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAP2K2 is over-expressed in tumor.

LIHC, KIRC, and LUSC are the cancer types where MAP2K2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP2K2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.576	<.001	9	view →
KIRC	Female	All	+0.357	<.001	9	view →
LUSC	All	II,III,IV	+0.609	<.001	6	view →
HNSC	Male	II,III,IV	+0.295	.005	6	view →
CHOL	Female	All	+2.093	<.001	5	view →
STAD	All	II,III,IV	+0.501	.004	4	view →
KIRP	All	II,III,IV	+0.448	.013	4	view →
UCEC	All	All	+0.361	.005	2	view →
PAAD	Male	All	+0.334	.038	2	view →
BLCA	All	All	+0.290	.032	2	view →
PRAD	All	All	+0.226	.033	2	view →
THCA	All	All	+0.131	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MAP2K2–LIHC

Open the LIHC breakdown →